Basic Information
Cinqaero
Regulatory Information
EMEA/H/C/003912
August 15, 2016
June 22, 2016
12
April 11, 2025
Company Information
the netherlands
Swensweg 5 2031GA Haarlem
Teva Pharma B.V.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Cinqaero. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cinqaero. For practical information about using Cinqaero, patients should read the package leaflet or contact their doctor or pharmacist.